 | Up a level |
Journal Article
Abrahamyan, S., Eberspaecher, B., Ambrosius, B., Hessler, N., Antony, G., Koenig, I. R., Hoshi, M. -M., Aly, L., Luessi, F., Groppa, S., Klotz, L., Meuth, S. G., Tackenberg, B., Stoppe, M., Bergh, F. Then, Tumani, H., Kuempfel, T., Stangel, M., Heesen, C., Wildemann, B., Paul, F., Bayas, A., Warnke, C., Weber, F., Linker, R. A., Ziemann, U., Zettl, U. K., Zipp, F., Wiendl, H., Hemmer, B., Gold, R., Salmen, A. and Ruprecht, K. (2018). Absence of Epstein-Barr virus seronegativity in a large cohort of patients with early multiple sclerosis. Mult. Scler. J., 24. S. 981 - 983. LONDON: SAGE PUBLICATIONS LTD. ISSN 1477-0970
Ambrosius, B., Hessler, N., Antony, G., Konig, I. R., Hoshi, M-M., Aly, L., Luessi, F., Groppa, S., Klotz, L., Meuth, S. G., Tackenberg, B., Stoppe, M., Bergh, F. Then, Tumani, H., Kuempfel, T., Stangel, M., Heesen, C., Wildemann, B., Paul, F., Bayas, A., Warnke, C., Weber, F., Linker, R. A., Ziemann, U., Zettl, U. K., Zipp, F., Wiendl, H., Hemmer, B., Gold, R. and Salmen, A. (2018). Changes of disease characteristics and disease-modifying treatment within one year in the National German MS cohort. Mult. Scler. J., 24. S. 554 - 557. LONDON: SAGE PUBLICATIONS LTD. ISSN 1477-0970
Gass, A., Wurfel, J., Kompan, I., Gregori, J., Ziemssen, T., Limmroth, V., Bayas, A., Haas, J., Linker, R., Maeurer, M., Stangel, M., Tackenberg, B., Meergans, M., Harlin, O. and Hartung, H-P (2017). TRUST-Study: Methods of an Optional MRI-Safety Surveillance for Progressive Multifocal Leukoencephalopathy (PML) in Relapsing-Remitting Multiple Sclerosis Patients Treated with Natalizumab. Mult. Scler. J., 23 (2). S. 338 - 339. LONDON: SAGE PUBLICATIONS LTD. ISSN 1477-0970
Gass, A., Wurfel, J., Kompan, I., Gregori, J., Ziemssen, T., Limmroth, V., Bayas, A., Haas, J., Linker, R., Maeurer, M., Stangel, M., Tackenberg, B., Meergans, M., Harlin, O. and Hartung, H. -P. (2016). TRUST-Study: methods of an optional MRI-safety surveillance for progressive multifocal leukoencephalopathy (PML) in relapsing remitting multiple sclerosis patients treated with Natalizumab. Mult. Scler. J., 22. S. 652 - 654. LONDON: SAGE PUBLICATIONS LTD. ISSN 1477-0970
Hartung, H-P, Ziemssen, T., Bayas, A., Tackenberg, B., Wuerfel, J., Limmroth, V., Linker, R., Maeurer, M., Haas, J., Stangel, M., Harlin, O., Winterstein, C., Meergans, M., Wernsdoerfer, C. and Gass, A. (2014). TRUST study design-a study to evaluate an integrated approach for optimized patient management in multiple sclerosis patients treated with natalizumab. Mult. Scler. J., 20. S. 111 - 112. LONDON: SAGE PUBLICATIONS LTD. ISSN 1477-0970
Hartung, H-P., Gass, A., Wuerfel, J., Bayas, A., Tackenberg, B., Limmroth, V., Linker, R., Maeurer, M., Haas, J., Stangel, M. and Ziemssen, T. (2017). TRUST - evaluation of baseline data to investigate an integrated approach for optimised patient management in multiple sclerosis patients treated with natalizumab. Mult. Scler. J., 23. S. 905 - 907. LONDON: SAGE PUBLICATIONS LTD. ISSN 1477-0970
Huss, A., Otto, M., Tackenberg, B., Stangel, M., Aktas, O., Meuth, S., Gross, C. C., Bayas, A., Wildemann, B., Luessi, F., Seipelt, M., Puetz, M., Antony, G., Weber, F., Uhr, M., Bischof', F., Ruprecht, K., Buck, D., Retzlaff, N., Zettl, U. K., Haghikia, A., Lukas, C., Hartung, H. -P., Bergh, F. Then, Warnke, C., Zipp, F., Wiendl, H., Hemmer, B., Gold, R. and Tumani, H. (2018). Prospective multicenter validation of CSF protein biomarkers in patients with CIS and early MS. Mult. Scler. J., 24. S. 656 - 658. LONDON: SAGE PUBLICATIONS LTD. ISSN 1477-0970